Tanski William J, Nicholl Suzanne M, Kim Dong, Fegley Allison J, Roztocil Elisa, Davies Mark G
Division of Vascular Surgery, Vascular Biology and Therapeutics Program, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA.
J Vasc Surg. 2005 Jan;41(1):91-8. doi: 10.1016/j.jvs.2004.08.058.
Vascular smooth muscle cell (SMC) migration is an important component of the development of intimal hyperplasia. Sphingosine-1-phosphate (S-1-P) is a lipid released from activated platelets with numerous cellular effects including the stimulation of SMC migration in vitro. We examined the role of the mammalian target of rapamycin and ribosomal p70S6 kinase (p70S6K) in S-1-P-induced SMC migration .
Rat arterial SMCs were cultured in vitro. Linear wound and Boyden microchemotaxis assays of migration were performed in the presence of S-1-P (0.01 to 100 micromol/L) with and without rapamycin (10 nmol/L). Western blotting was performed for phosphorylated and total p70S6K, ERK1/2, and p38(MAPK) after stimulation with S-1-P (0.1 micromol/L), with and without rapamycin pretreatment. Phosphorylation of p70S6K was also assayed after S-1-P treatment in the presence and absence of inhibitors of PI3 kinase (wortmannin, WN, and LY294002, LY), Akt (AktI), p38(MAPK) (SB203580), and MEK1 (PD98059).
S-1-P stimulated migration of SMCs in both linear wound and Boyden chamber assays compared to control (P < .05); these responses were inhibited by rapamycin to below the level of control (P < .05 vs S-1-P alone for both assays) in a dose-dependent manner (inhibitory concentration of 50%, 10 nmol/L). S-1-P stimulated phosphorylation of ERK1/2, p38(MAPK), and p70S6K, which peaked at 5 minutes for ERK1/2 and p38(MAPK) and10 minutes for p70S6K (2-fold increase over control for each, P < .05). Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation. Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K. AktI and SB203580 had no effect on p70S6K, whereas PD98059 had a marginal effect.
S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved. This mechanism likely involves modulation of the ERK1/2 pathway. S-1-P stimulates phosphorylation of p70S6K in a MEK1-dependent, PI3 kinase-dependent, but Akt-independent manner.
血管平滑肌细胞(SMC)迁移是内膜增生发展的一个重要组成部分。1-磷酸鞘氨醇(S-1-P)是一种从活化血小板释放的脂质,具有多种细胞效应,包括在体外刺激SMC迁移。我们研究了雷帕霉素的哺乳动物靶点和核糖体p70S6激酶(p70S6K)在S-1-P诱导的SMC迁移中的作用。
体外培养大鼠动脉SMC。在有和没有雷帕霉素(10 nmol/L)存在的情况下,用S-1-P(0.01至100 μmol/L)进行线性伤口和博伊登微趋化性迁移试验。在用S-1-P(0.1 μmol/L)刺激后,有和没有雷帕霉素预处理的情况下,对磷酸化和总p70S6K、ERK1/2和p38(MAPK)进行蛋白质印迹分析。在有和没有PI3激酶抑制剂(渥曼青霉素,WN,和LY294002,LY)、Akt(AktI)、p38(MAPK)(SB203580)和MEK1(PD98059)存在的情况下,用S-1-P处理后也检测p70S6K的磷酸化。
与对照相比,S-1-P在线性伤口和博伊登小室试验中均刺激了SMC的迁移(P <.05);这些反应被雷帕霉素以剂量依赖性方式抑制至对照水平以下(两种试验中与单独使用S-1-P相比,P <.05)(50%抑制浓度,10 nmol/L)。S-1-P刺激ERK1/2、p38(MAPK)和p70S6K的磷酸化,ERK1/2和p38(MAPK)在5分钟时达到峰值,p70S6K在10分钟时达到峰值(每种均比对照增加2倍,P <.05)。雷帕霉素阻止了Thr 389位点的p70S6K磷酸化(这与酶活性相关),降低了ERK1/2磷酸化,但对Thr 421/Ser 424位点或p38(MAPK)磷酸化没有影响。渥曼青霉素和LY294002抑制p70S6K的Thr 389位点的磷酸化。AktI和SB203580对p70S6K没有影响,而PD98059有轻微影响。
雷帕霉素完全抑制了S-1-P诱导的SMC迁移,表明p70S6K途径参与其中。这种机制可能涉及ERK1/2途径的调节。S-1-P以MEK1依赖性、PI3激酶依赖性但Akt非依赖性方式刺激p70S6K的磷酸化。